ArticleDrug and alcohol dependence2019
The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting.
Article in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Implementation of Jail and Prison-Based Medication Treatment for Opioid Use Disorder Programs: A Narrative Synthesis.Medical care research and review : MCRR · 2025Pooled it
- A Qualitative Systematic Review of Access to Substance Use Disorder Care in the United States Criminal Justice System.International journal of environmental research and public health · 2022Pooled it
- Multilevel determinants of medication preferences for opioid use disorder among criminal-legal-involved populations: Insights from a scoping review.Drug and alcohol dependence reports · 2025Review
- MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting.BMJ open · 2025Article
- State-Mandated Opioid Use Disorder Treatment In Maryland Jails Helped Patients Recover Despite Gaps In Care.Health affairs (Project Hope) · 2025Article
- An investigation of drug use among first-time arrestees from 25 county jails across the United States in 2023.Addiction science & clinical practice · 2025Article
- Medication for opioid use disorder service delivery in carceral facilities: update and summary report.Health & justice · 2025Review
- "Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison.Journal of substance use and addiction treatment · 2025Article
- Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders.Addiction science & clinical practice · 2024Article
- Framework for opioid use disorder screening and diagnosis in carceral settings.The International journal on drug policy · 2024Article
- Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis.Health & justice · 2024Article
- Identifying structural risk factors for overdose following incarceration: a concept mapping study.Health & justice · 2024Article
- Attitudes of Black American Christian church leaders toward Opioid Use Disorder, overdoses, and harm reduction: a qualitative study.Frontiers in psychiatry · 2024Article
- Treatment preference for opioid use disorder among people who are incarcerated.Journal of substance abuse treatment · 2022Article
- "It's probably going to save my life;" attitudes towards treatment among people incarcerated in the era of fentanyl.Drug and alcohol dependence · 2022Article
- Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.Lancet (London, England) · 2022Review
- Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.Substance abuse · 2022Article
- Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).Journal of substance abuse treatment · 2021Article
- Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services.Journal of substance abuse treatment · 2021Article
- COVID-19 and treating incarcerated populations for opioid use disorder.Journal of substance abuse treatment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
The prevalence of opioid use disorders among people who are incarcerated is high. People who are released from incarceration are at increased risk for overdose. The current study details the first year of implementation of a state-wide medications for addiction treatment (MAT) program in a unified jail and prison setting at the Rhode Island Department of Corrections in Cranston, Rhode Island. We conducted 40 semi-structured, qualitative interviews with people who were incarcerated and concurrently enrolled in the MAT program. Analysis employed a general, inductive approach in NVivo 12. We found that a majority of participants discussed program benefits such as reduced withdrawal symptoms, decreased prevalence of illicit drug use in the facility, improved general environment at the RIDOC, and increased post-release intentions to continue MAT. Suggested areas of improvement include reducing delays to first dose, increasing access to other recovery services in combination with MAT, improving staff training on stigma, and earlier access to medical discharge planning information prior to release. Our findings suggest that correctional MAT programs are acceptable to targeted populations and are a feasible intervention that may be transferable to other states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.